Rosiglitazone inhibits K(v)4.3 potassium channels by open-channel block and acceleration of closed-state inactivation

BACKGROUND AND PURPOSE: Rosiglitazone is a widely used oral hypoglycaemic agent, which improves insulin resistance in type 2 diabetes. Chronic rosiglitazone treatment is associated with a number of adverse cardiac events. The present study was designed to characterize the effects of rosiglitazone on...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeong, I, Choi, BH, Hahn, SJ
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Ltd 2011
Subjects:
Research Papers with Commentary
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3101614/
https://ncbi.nlm.nih.gov/pubmed/21232039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2011.01210.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items